rAAV Vector eEF1A2 Delivery CNS Gene Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an unmet need for effective therapy for EEF1A2-related diseases, which are rare and poorly understood, with challenges in delivering gene therapy to the central nervous system due to its complexity and unpredictability.
Innovation Solution
The use of adeno-associated virus (AAV)-based delivery of a polynucleotide encoding eEF1A2 or a functional variant, linked to a neuron-specific promoter, such as the human synapsin 1 promoter, to treat and prevent neurological diseases by administering the recombinant AAV virion intracerebrally and/or intravenously.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If gene therapy is delivered to the central nervous system, then therapeutic effect is achieved, but delivery complexity and unpredictability increase
Solution Approach 1:
The patent uses adeno-associated virus (AAV) as an intermediary vector to deliver the eEF1A2 gene to the central nervous system. The AAV capsid serves as a mediator that facilitates viral entry and gene delivery across the blood-brain barrier, reducing delivery complexity while maintaining therapeutic efficacy. The neuron-specific synapsin 1 promoter acts as another intermediary that ensures targeted gene expression in neuronal cells.
Solution Approach 2:
The patent employs a neuron-specific promoter (synapsin 1) that provides localized gene expression specifically in neuronal cells of the central nervous system. This local quality approach ensures that the therapeutic gene is expressed only where needed (in neurons) rather than systemically, reducing off-target effects and improving delivery predictability while maintaining therapeutic reliability.
2Reliability
If wild-type EEF1A2 is expressed during development, then wst genotype is complemented, but postnatal rescue effectiveness is uncertain
Solution Approach 1:
The patent uses neonatal gene delivery to establish eEF1A2 expression before the onset of severe neurological symptoms. By administering the AAV vector during the neonatal period (postnatal days 1-7), the therapy performs preliminary action that prevents disease progression rather than attempting to rescue already-damaged neurons, improving both effectiveness and timing predictability.
3Reliability
If AAV vector is used for gene delivery, then neuronal expression is achieved, but delivery to CNS remains challenging
Solution Approach 1:
The AAV vector serves as an intermediary delivery system that simplifies gene delivery to the central nervous system. The viral capsid mediates entry into neurons, and the synapsin 1 promoter mediates specific neuronal expression, making the overall delivery process more efficient and predictable compared to non-viral methods.
Solution Approach 2:
The patent optimizes delivery parameters including administering the AAV vector at high doses (2×10^11 to 2×10^12 viral genomes per pup) during the neonatal period when the blood-brain barrier is more permeable. This parameter change approach improves delivery ease by exploiting developmental windows when CNS delivery is more efficient.
Data Source
AI summary
Provided herein is a gene therapy for neurological disease using a recombinant adeno-associated virus (rAAV) virion as a vector to express an eEF1A2 protein or functional variant thereof. The rAAV virion may use a neuron-specific promoter, e.g., a human synapsin 1 (hSYN) promoter. The capsid may be an AAV9 capsid or functional variant thereof. Other promoters or capsids may be used. Further provided are methods of treatment, such as by intracerebrally and/or intravenously of the rAAV virion, and other compositions and methods.